199 related articles for article (PubMed ID: 16461303)
21. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
Yata K; Yaccoby S
Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms underlying catabolic and anabolic functions of parathyroid hormone on bone by combination of culture systems of mouse cells.
Shinoda Y; Kawaguchi H; Higashikawa A; Hirata M; Miura T; Saito T; Nakamura K; Chung UI; Ogata N
J Cell Biochem; 2010 Mar; 109(4):755-63. PubMed ID: 20058231
[TBL] [Abstract][Full Text] [Related]
23. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma.
Li B; Shi M; Li J; Zhang H; Chen B; Chen L; Gao W; Giuliani N; Zhao RC
Stem Cells Dev; 2007 Dec; 16(6):921-30. PubMed ID: 17927494
[TBL] [Abstract][Full Text] [Related]
24. Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease.
Dotterweich J; Schlegelmilch K; Keller A; Geyer B; Schneider D; Zeck S; Tower RJ; Ebert R; Jakob F; Schütze N
Bone; 2016 Dec; 93():155-166. PubMed ID: 27519972
[TBL] [Abstract][Full Text] [Related]
25. [Effects of the osteoclast in pathogenesis of multiple myeloma].
Zhang JH; Fu JX; Zhang XH; Sun Y
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):323-6. PubMed ID: 17877161
[TBL] [Abstract][Full Text] [Related]
26. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
Tanaka Y; Abe M; Hiasa M; Oda A; Amou H; Nakano A; Takeuchi K; Kitazoe K; Kido S; Inoue D; Moriyama K; Hashimoto T; Ozaki S; Matsumoto T
Clin Cancer Res; 2007 Feb; 13(3):816-23. PubMed ID: 17289872
[TBL] [Abstract][Full Text] [Related]
27. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
Yaccoby S; Pearse RN; Johnson CL; Barlogie B; Choi Y; Epstein J
Br J Haematol; 2002 Feb; 116(2):278-90. PubMed ID: 11841428
[TBL] [Abstract][Full Text] [Related]
28. 17beta-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro.
Li Q; Yu K; Tian X; Kong F; You Y; Chen Z; Zou P
Leuk Res; 2009 Sep; 33(9):1266-71. PubMed ID: 19167063
[TBL] [Abstract][Full Text] [Related]
29. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model.
Reagan MR; Mishima Y; Glavey SV; Zhang Y; Manier S; Lu ZN; Memarzadeh M; Zhang Y; Sacco A; Aljawai Y; Shi J; Tai YT; Ready JE; Kaplan DL; Roccaro AM; Ghobrial IM
Blood; 2014 Nov; 124(22):3250-9. PubMed ID: 25205118
[TBL] [Abstract][Full Text] [Related]
30. The mammalian lectin galectin-8 induces RANKL expression, osteoclastogenesis, and bone mass reduction in mice.
Vinik Y; Shatz-Azoulay H; Vivanti A; Hever N; Levy Y; Karmona R; Brumfeld V; Baraghithy S; Attar-Lamdar M; Boura-Halfon S; Bab I; Zick Y
Elife; 2015 May; 4():e05914. PubMed ID: 25955862
[TBL] [Abstract][Full Text] [Related]
31. Mesenchymal Stem Cells Repress Osteoblast Differentiation Under Osteogenic-Inducing Conditions.
Santos TS; Abuna RP; Castro Raucci LM; Teixeira LN; de Oliveira PT; Beloti MM; Rosa AL
J Cell Biochem; 2015 Dec; 116(12):2896-902. PubMed ID: 26013001
[TBL] [Abstract][Full Text] [Related]
32. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
[TBL] [Abstract][Full Text] [Related]
33. Small interfering RNA silencing of interleukin-6 in mesenchymal stromal cells inhibits multiple myeloma cell growth.
Teoh HK; Chong PP; Abdullah M; Sekawi Z; Tan GC; Leong CF; Cheong SK
Leuk Res; 2016 Jan; 40():44-53. PubMed ID: 26626206
[TBL] [Abstract][Full Text] [Related]
34. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
35. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
Andersen TL; Søe K; Sondergaard TE; Plesner T; Delaisse JM
Br J Haematol; 2010 Feb; 148(4):551-61. PubMed ID: 19919653
[TBL] [Abstract][Full Text] [Related]
36. Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.
Teramachi J; Silbermann R; Yang P; Zhao W; Mohammad KS; Guo J; Anderson JL; Zhou D; Feng R; Myint KZ; Maertz N; Beumer JH; Eiseman JL; Windle JJ; Xie XQ; Roodman GD; Kurihara N
Leukemia; 2016 Feb; 30(2):390-8. PubMed ID: 26286116
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
38. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
[TBL] [Abstract][Full Text] [Related]
39. Rat hindlimb unloading by tail suspension reduces osteoblast differentiation, induces IL-6 secretion, and increases bone resorption in ex vivo cultures.
Grano M; Mori G; Minielli V; Barou O; Colucci S; Giannelli G; Alexandre C; Zallone AZ; Vico L
Calcif Tissue Int; 2002 Mar; 70(3):176-85. PubMed ID: 11907715
[TBL] [Abstract][Full Text] [Related]
40. Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher disease.
Reed MC; Schiffer C; Heales S; Mehta AB; Hughes DA
Mol Genet Metab; 2018 Aug; 124(4):278-286. PubMed ID: 29934064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
